|
1
|
Akcay MN: Metastatic disease in the
breast. Breast. 11:526–528. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Munch-Petersen B, Piskur J and Sondergaard
L: Four deoxynucleoside kinase activities from Drosophila
melanogaster are contained within a single monomeric enzyme, a
new multifunctional deoxynucleoside kinase. J Biol Chem.
273:3926–3931. 1998.PubMed/NCBI
|
|
3
|
Munch-Petersen B, Knecht W, Lenz C,
Sondergaard L and Piskur J: Functional expression of a
multisubstrate deoxyribonucleoside kinase from Drosophila
melanogaster and its C-terminal deletion mutants. J Biol Chem.
275:6673–6679. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ito M, Suda Y, Harashima H and Kamiya H:
Cytotoxic effect of Drosophila deoxynucleoside kinase gene
on replicating plasmid in HeLa cells. Biol Pharm Bull.
33:1223–1227. 2010.
|
|
5
|
Zhu Z, Mao L, Zhao L, et al: Synergistic
therapeutic effect in gastric cancer cells produced by oncolytic
adenovirus encoding Drosophila melanogaster
deoxyribonucleoside kinase. Cancer Biol Ther. 11:874–882. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma S, Zhao L, Zhu Z, et al: The
multisubstrate deoxyribonucleoside kinase of Drosophila
melanogaster as a therapeutic suicide gene of breast cancer
cells. J Gene Med. 13:305–311. 2011.
|
|
7
|
Ma S, Qu W, Mao L, et al: Antitumor
effects of oncolytic adenovirus armed with Drosophila
melanogaster deoxyribonucleoside kinase in colorectal cancer.
Oncol Rep. 27:1443–1450. 2012.PubMed/NCBI
|
|
8
|
Zhang N, Zhao L, Ma S, Gu M and Zheng X:
Lentivirus-mediated expression of Drosophila melanogaster
deoxyribonucleoside kinase driven by the hTERT promoter combined
with gemcitabine: a potential strategy for cancer therapy. Int J
Mol Med. 30:659–665. 2012.
|
|
9
|
Kojaoghlanian T, Flomenberg P and Horwitz
MS: The impact of adenovirus infection on the immunocompromised
host. Rev Med Virol. 13:155–171. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Poller W, Fechner H, Noutsias M, Tschoepe
C and Schultheiss HP: Highly variable expression of virus receptors
in the human cardiovascular system. Implications for cardiotropic
viral infections and gene therapy. Z Kardiol. 91:978–991. 2002.
View Article : Google Scholar
|
|
11
|
VandenDriessche T, Collen D and Chuah MK:
Viral vector-mediated gene therapy for hemophilia. Curr Gene Ther.
1:301–315. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sugiyama O, An DS, Kung SP, et al:
Lentivirus-mediated gene transfer induces long-term transgene
expression of BMP-2 in vitro and new bone formation in vivo. Mol
Ther. 11:390–398. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sandrini MP, Clausen AR, On SL, Aarestrup
FM, Munch-Petersen B and Piskur J: Nucleoside analogues are
activated by bacterial deoxyribonucleoside kinases in a
species-specific manner. J Antimicrob Chemother. 60:510–520. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bonini C, Bondanza A, Perna SK, et al: The
suicide gene therapy challenge: how to improve a successful gene
therapy approach. Mol Ther. 15:1248–1252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yazawa K, Fisher WE and Brunicardi FC:
Current progress in suicide gene therapy for cancer. World J Surg.
26:783–789. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bastide C, Maroc N, Bladou F, et al:
Expression of a model gene in prostate cancer cells lentivirally
transduced in vitro and in vivo. Prostate Cancer Prostatic Dis.
6:228–234. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Johansson M, Brismar S and Karlsson A:
Human deoxycytidine kinase is located in the cell nucleus. Proc
Natl Acad Sci USA. 94:11941–11945. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu C, Johansson M and Karlsson A:
Incorporation of nucleoside analogs into nuclear or mitochondrial
DNA is determined by the intracellular phosphorylation site. J Biol
Chem. 275:26727–26731. 2000.PubMed/NCBI
|
|
19
|
Knecht W, Sandrini MP, Johansson K, Eklund
H, Munch-Petersen B and Piskur J: A few amino acid substitutions
can convert deoxyribonucleoside kinase specificity from pyrimidines
to purines. EMBO J. 21:1873–1880. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Solaroli N, Bjerke M, Amiri MH, Johansson
M and Karlsson A: Active site mutants of Drosophila
melanogaster multisubstrate deoxyribonucleoside kinase. Eur J
Biochem. 270:2879–2884. 2003.
|
|
21
|
Zhu Z, Ma S, Zhao L, et al:
Adenovirus-mediated Drosophila melanogaster
deoxyribonucleoside kinase mutants combined with gemcitabine harbor
a safe cancer treatment profile. Int J Oncol. 38:745–753. 2011.
|
|
22
|
Knecht W, Mikkelsen NE, Clausen AR, et al:
Drosophila melanogaster deoxyribonucleoside kinase activates
gemcitabine. Biochem Biophys Res Commun. 382:430–433. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mueller C and Flotte TR: Clinical gene
therapy using recombinant adeno-associated virus vectors. Gene
Ther. 15:858–863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Calcedo R, Vandenberghe LH, Gao G, Lin J
and Wilson JM: Worldwide epidemiology of neutralizing antibodies to
adeno-associated viruses. J Infect Dis. 199:381–390. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu J, Saghizadeh M, Tuli SS, et al:
Different tropism of adenoviruses and adeno-associated viruses to
corneal cells: implications for corneal gene therapy. Mol Vis.
14:2087–2096. 2008.PubMed/NCBI
|
|
26
|
Sharma A, Tovey JC, Ghosh A and Mohan RR:
AAV serotype influences gene transfer in corneal stroma in vivo.
Exp Eye Res. 91:440–448. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Donsante A, Miller DG, Li Y, et al: AAV
vector integration sites in mouse hepatocellular carcinoma.
Science. 317:4772007. View Article : Google Scholar : PubMed/NCBI
|
